Progesterone vaginal insert
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Progesterone vaginal insert
- Generic name
- PROGESTERONE
- Manufacturer
- XIROMED, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 473ab609-5b9e-3cb8-68d5-4a459a2ea6c1
- SPL ID
- 30947aaa-8093-2fb1-65a6-fed969c7bed9
- Version
- 5
- Effective date
- 2026-10-05
- Source export date
- 2026-11-13
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:55:17
| Harmonized routes |
|---|
| VAGINAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | ANDA | 218391 | derived:openfda.application_number |
| application number | ANDA218391 | openfda.application_number | |
| brand name | Progesterone vaginal insert | openfda.brand_name | |
| generic name | PROGESTERONE | openfda.generic_name | |
| manufacturer name | XIROMED, LLC | openfda.manufacturer_name | |
| ndc | package | 70700-201-70 | openfda.package_ndc |
| ndc | package | 70700-201-69 | openfda.package_ndc |
| ndc | package | 70700-201-68 | openfda.package_ndc |
| ndc | product | 70700-201 | openfda.product_ndc |
| ndc11 | package | 70700020168 | derived:openfda.package_ndc |
| ndc11 | package | 70700020170 | derived:openfda.package_ndc |
| ndc11 | package | 70700020169 | derived:openfda.package_ndc |
| rxcui | 725094 | openfda.rxcui | |
| spl id | 30947aaa-8093-2fb1-65a6-fed969c7bed9 | id | |
| spl set id | 473ab609-5b9e-3cb8-68d5-4a459a2ea6c1 | set_id | |
| unii | 4G7DS2Q64Y | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Cardiovascular or Cerebrovascular Disorders: Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with progesterone vaginal insert. Discontinue progesterone vaginal insert if any of these are suspected. ( 5.1 ) Depression: Closely observe progesteronevaginal insert-treated women with a history of depression. Consider progesterone vaginal insert discontinuation if symptoms worsen. ( 5.2 ) 5.1 Cardiovascular or Cerebrovascular Disorders Life-threatening arterial or venous thromboembolic disorders may occur during hormone treatment, including treatment with progesterone vaginal insert. The healthcare provider should be alert to earliest signs of myocardial infarction, cerebrovascular disorders, arterial or venous thromboembolism (venous thromboembolism or pulmonary embolism), thrombophlebitis, or retinal thrombosis. Progesterone vaginal insert should be discontinued if any of these are suspected. 5.2 Depression Progesterone vaginal insert-treated women with a history of depression should be closely observed. Consider progesterone vaginal insert discontinuation if symptoms worsen.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions reported (greater than 2%) were post-oocyte retrieval pain, abdominal pain, nausea, and ovarian hyperstimulation syndrome. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Xiromed, LLC at 1-844-XIROMED (1-844-947-6633) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Study Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data reflect exposure to progesterone vaginal insert in 808 infertile women in a single Assisted Reproductive Technology 10 week clinical study conducted in the U.S. [see Clinical Studies (14) ]. Progesterone vaginal insert was studied at vaginally administered doses of 100 mg twice daily and 100 mg three times daily for 10 weeks and compared to a vaginally administered active comparator. The adverse reactions that occurred at a rate greater than or equal to 2% in either progesterone vaginal insert group are summarized in Table 1. Other less common reported adverse reactions in progesterone vaginal insert-treated women included vaginal irritation, itching, burning, discomfort, urticaria, and peripheral edema. Table 1: Number and Frequency of Reported Adverse Reactions in Infertile Women Treated with ProgesteroneVaginal Insert in an Assisted Reproductive Technology Study Progesterone Vaginal Insert 100 mg twice daily (N=404) Progesterone Vaginal Insert 100 mg three times daily (N=404) Post-oocyte retrieval pain 115 (28%) 102 (25%) Abdominal pain 50 (12%) 50 (12%) Nausea 32 (8%) 29 (7%) Ovarian hyperstimulation syndrome 30 (7%) 27 (7%) Abdominal distension 18 (4%) 17 (4%) Headache 15 (4%) 13 (3%) Uterine spasm 15 (4%) 11 (3%) Vaginal bleeding 13 (3%) 14 (3%) Vomiting 13 (3%) 9 (2%) Urinary tract infection 9 (2%) 4 (1%) Constipation 9 (2%) 14 (3%) Fatigue 7 (2%) 12 (3%) Adverse Reactions from Other Progesterone Products Adverse reactions from other progesterone products included breast tenderness, bloating, mood swings, irritability, and drowsiness.
adverse reactions table
<table> <col/> <col/> <col/> <tbody> <tr> <td align="justify" valign="top"/> <td align="center" valign="top"> <paragraph> <content styleCode="bold">Progesterone Vaginal Insert</content> </paragraph> <paragraph> <content styleCode="bold">100 mg twice daily</content> </paragraph> <paragraph> <content styleCode="bold">(N=404)</content> </paragraph> </td> <td align="center" valign="top"> <paragraph> <content styleCode="bold">Progesterone Vaginal Insert</content> </paragraph> <paragraph> <content styleCode="bold">100 mg three times daily</content> </paragraph> <paragraph> <content styleCode="bold">(N=404)</content> </paragraph> </td> </tr> <tr> <td align="justify" valign="top">Post-oocyte retrieval pain</td> <td align="center" valign="top">115 (28%)</td> <td align="center" valign="top">102 (25%)</td> </tr> <tr> <td align="justify" valign="top">Abdominal pain</td> <td align="center" valign="top">50 (12%)</td> <td align="center" valign="top">50 (12%)</td> </tr> <tr> <td align="justify" valign="top">Nausea</td> <td align="center" valign="top">32 (8%)</td> <td align="center" valign="top">29 (7%)</td> </tr> <tr> <td align="justify" valign="top">Ovarian hyperstimulation syndrome</td> <td align="center" valign="top">30 (7%)</td> <td align="center" valign="top">27 (7%)</td> </tr> <tr> <td align="justify" valign="top">Abdominal distension</td> <td align="center" valign="top">18 (4%)</td> <td align="center" valign="top">17 (4%)</td> </tr> <tr> <td align="justify" valign="top">Headache</td> <td align="center" valign="top">15 (4%)</td> <td align="center" valign="top">13 (3%)</td> </tr> <tr> <td align="justify" valign="top">Uterine spasm</td> <td align="center" valign="top">15 (4%)</td> <td align="center" valign="top">11 (3%)</td> </tr> <tr> <td align="justify" valign="top">Vaginal bleeding</td> <td align="center" valign="top">13 (3%)</td> <td align="center" valign="top">14 (3%)</td> </tr> <tr> <td align="justify" valign="top">Vomiting</td> <td align="center" valign="top">13 (3%)</td> <td align="center" valign="top">9 (2%)</td> </tr> <tr> <td align="justify" valign="top">Urinary tract infection</td> <td align="center" valign="top">9 (2%)</td> <td align="center" valign="top">4 (1%)</td> </tr> <tr> <td align="justify" valign="top">Constipation</td> <td align="center" valign="top">9 (2%)</td> <td align="center" valign="top">14 (3%)</td> </tr> <tr> <td align="justify" valign="top">Fatigue</td> <td align="center" valign="top">7 (2%)</td> <td align="center" valign="top">12 (3%)</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.